Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2019-12-04 M&A Activity
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
S-4
M&A Activity Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which is used for registering securities in connection with mergers and acquisitions. It includes detailed information about the merger proposal between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd., including share exchange ratios, meeting notices for shareholders, and merger agreement details. The presence of a joint proxy statement/prospectus and extensive merger-related disclosures indicates this is a filing related to M&A activity. It is not an annual report, earnings release, or other financial report, but a regulatory filing specifically for a merger transaction. Therefore, the appropriate classification is 'M&A Activity' (Code: TAR). The document length and content confirm it is the full filing, not just an announcement or summary.
2019-12-04 English
425 Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Menlo Therapeutics Inc. It reports the entry into an Amendment No. 1 to a Merger Agreement dated December 4, 2019, involving Menlo and Foamix Pharmaceuticals. The text includes detailed information about the merger amendment, references to proxy statements, and SEC filings related to the merger. The document is not a full annual or quarterly report, nor is it an earnings release or proxy solicitation itself. It is a regulatory filing reporting a material definitive agreement related to a merger. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain full financial statements or detailed financial analysis. The document length (7387 characters) and content confirm it is not merely an announcement of a report but a substantive filing about a merger amendment. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-12-04 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934, which are commonly used for merger communications. It discusses a merger agreement between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd., including details about employee compensation, severance, stock options, and the merger timeline. The document also references the upcoming filing of a Registration Statement on Form S-4 containing a joint proxy statement/prospectus related to the merger. The content is focused on merger-related information and communications to shareholders and employees, consistent with a merger communication filing. It is not a full annual report, earnings release, or proxy statement itself, but a communication under Rule 425 providing merger-related information. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (15,000 characters) and detailed content support this classification with high confidence.
2019-11-21 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details an Agreement and Plan of Merger between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd., including terms of the merger, governance changes, conditions to closing, and termination rights. This is a clear announcement of a merger transaction and related corporate actions, not a full annual or quarterly report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement, but rather a regulatory filing disclosing a material definitive agreement related to M&A activity. Given the detailed merger agreement and terms, the appropriate classification is M&A Activity (Code: TAR). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive filing about the merger.
2019-11-12 English
425 Filing
Merger & Acquisition Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 12, 2019, reporting the entry into a material definitive agreement, specifically an Agreement and Plan of Merger between Foamix Pharmaceuticals Ltd. and Menlo Therapeutics, Inc. The text details the terms of the merger, merger consideration, governance changes, conditions to the merger, and other related terms. This is a current report disclosing a significant corporate transaction (merger agreement) rather than a full annual or quarterly report, earnings release, or other types of filings. The presence of detailed merger terms and conditions aligns with filings related to M&A activity. Therefore, the document should be classified under Merger & Acquisition (MA).
2019-11-12 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934, which are commonly used for merger communications. It discusses a proposed merger between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd., including details about the transaction rationale, integration plans, and forward-looking statements. It references a forthcoming joint proxy statement/prospectus on Form S-4 to be filed with the SEC, which is typical for merger-related filings. The document is a communication related to the merger proposal rather than a formal proxy statement or merger agreement itself. Given the nature of the content and the regulatory references, this filing fits the category of Merger & Acquisition (MA) filings, which include merger communications such as Form 425 filings. The document length (10,746 characters) supports that it is a substantive communication rather than a brief announcement or notice.
2019-11-12 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.